A TECHNOLOGY THAT DETECTS THE PRESENCE OF NEUTRALISING ANTIBODIES AGAINST SARS-CoV-2
In August 2023, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool signed a worldwide licence with the University of Chile for its technology designed as a system for quantification of neutralizing antibodies against SARS-CoV-2. This technology can be used in the facility using heightened control measures similar to biosafety level 2 laboratories.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for this technology by submitting an e-mail to CTAPDiagnostics@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
|Aim of the Licence||To facilitate the worldwide use of technology which allows to detect the presence of neutralising antibodies against SARS-CoV-2.|
|Products||Any product that uses the licensed know-how or material.|
|Know‐how||The University will provide all necessary know-how and materials to the licensees, specified in the licence|
|Field of use||COVID-19|
|Territory||Worldwide. The sublicensee shall not be a commercial entity either incorporated or manufacturing the products in Chile.|
|Scope of the grant||Non-exclusive right to grant sublicences to develop the licensed know how/material into products, and to commercialize licensed products.|
|Term||10 years from the Effective Date|